The Competition and Consumer Commission of Singapore (CCCS) has granted conditional approval for the completed merger of two private clinical laboratories, after accepting four-year commitments from Pathology Asia Holdings (PAH).
PAH, a unit of private equity giant TPG Capital Asia, integrated the businesses of the two labs – Innovative Diagnostics and Quest Laboratories – after acquiring them last year.
Both labs provide in-vitro diagnostic (IVD) tests in Singapore, which can be used to detect diseases or other conditions and monitor a person’s health.
Pre-merger, Innovative, and Quest had been the closest competitors to each other, as they were the top two suppliers of IVD tests among private clinical labs in Singapore, CCCS announced on Monday, October 21.
Full Content: Business Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Withdraws Case Against Microsoft-Activision Merger, Citing Public Interest
May 23, 2025 by
CPI
Charter to Acquire Cox Communications in $35 Billion Deal
May 22, 2025 by
CPI
FTC Targets Media Watchdog Over Alleged Collusion Against Musk’s X
May 22, 2025 by
CPI
FTC Drops Antitrust Case Accusing Pepsi of Squeezing Small Retailers
May 22, 2025 by
CPI
Shein Warns of Higher Costs for French Shoppers Amid EU Fee Proposal
May 22, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Industrial Policy
May 21, 2025 by
CPI
Industrial Strategy and the Role of Competition – Taking a Business Lens
May 21, 2025 by
Marcus Bokkerink
Industrial Policy, Antitrust, and Economic Growth: Some Observations
May 21, 2025 by
David S. Evans
Bolder by Design: Crafting Pro-Competitive Industrial Policies For Complex Challenges
May 21, 2025 by
Antonio Capobianco & Beatriz Marques
Competition-Friendly Industrial Policy
May 21, 2025 by
Philippe Aghion, Mathias Dewatripont & Patrick Legros